Meihua Yu

Dr Meihua Yu is a Research Fellow in Cancer Immunotherapy at the Australian Institute for Bioengineering and Nanotechnology (AIBN). She received her PhD in Biomedical Engineering from AIBN, UQ in 2014. Throughout her research career, she has held full-time research positions from 2014 to 2021 at UQ following completion of her PhD, followed by a position as Research-Teaching Associate Prof at Shanghai University, China (2021-2025). She returned to AIBN in 2026 to continue her research program.

Dr Yu's current research focuses on materials-immunology for cancer treatment and prevention of infectious diseases. Dr Yu has published 95 papers (H-index, 40) in top international journals including Science Advances, Angewandte Chemie International Edition, Advanced Materials, Journal of the American Chemical Society, Journal of Immunology, and Chemical Society Reviews. Her innovative research has resulted in 1 international patents and 14 Chinese patents.

Dr Yu has secured competitive research funding over $1.0M from the ARC, NHMRC, Queensland Government, National Natural Science Foundation of China, Shanghai Municipality, and Zhejiang Province (e.g., UQ Early Career grants, ARC Linkage projects, Queensland Biomedical Assistance Fund, and the 2017 UQ Foundation Research Excellence Award).

Dr Yu has been awarded four prestigious national and state fellowships, including 2017 NHMRC Early Career Fellowship, 2016 Advance Queensland Early Career Research Fellowship, 2021 Shanghai Excellent Overseas Young Scientists, and 2022 Zhejiang Overseas Thousand Talents Program (relinquished). She has actively pursued commercial translation of her discoveries through strategic collaborations with industry partners, including Ridley, Ellume, and Jingang Medicines.

Dr Yu serves as an invited reviewer for national competitive grants and manuscripts for more than 40 international journals, including Med, ACS Nano, and Advanced Materials.